The popular varieties of injection collection are about to start fighting

Popular varieties of injection centralized procurement

Fighting is about to begin

October 9, 2021 is the deadline for the sixth batch of national centralized procurement (insulin special projects), which also shows that the sixth batch of centralized procurement is about to start

A Collected varieties

There are 3 types of injections in the first collection catalog: Pemetrexed disodium for injection, flurbiprofen axetil injection and dexmedetomidine hydrochloride injection

The fourth and fifth batches of centralized procurement will be implemented around May 2021 and October 2021 respectively.

Pemetrexed Disodium for Injection

From the PDB database, the sales of pemetrexed disodium for injection in the sample hospitals in 2020 were 1.

Based on the data for the first half of 2021, it can be predicted that sales and sales volume in 2021 will slightly increase compared to 2020

Flurbiprofen injection

In 2020, the sales of flurbiprofen axetil injection sample hospitals were 276 million yuan, and the sales volume has declined in the past four years

Judging from the data in the first half of 2021, it can be predicted that the sales and sales volume of flurbiprofen axetil injection in 2021 will increase compared to 2020, and the price will remain at the 2020 level

Dexmedetomidine Hydrochloride Injection

In 2020, the sales of dexmedetomidine hydrochloride injection in the sample hospitals were 983 million yuan, which was a decrease compared with the sales in 2019, but the average unit price was basically stable, mainly due to the decrease in sales volume

Based on the data in the first half of 2021, it can be predicted that the sales and sales volume of dexmedetomidine hydrochloride in 2021 will exceed those in 2019 and 2020

Paclitaxel for injection (albumin-bound type)

In 2020, the sales of paclitaxel for injection (albumin-binding type) in sample hospitals was 1.

Judging from the data in the first half of 2021, it can be predicted that the sales and sales volume of paclitaxel for injection (albumin-bound type) in 2021 will exceed those of the previous two years
.
From the perspective of the sales share in the first half of 2021, the product sales and sales volume of the selected manufacturers of CSPC accounted for 63% and 62%
.
The selected manufacturer Jiangsu Hengrui's product sales and sales volume accounted for 32% and 32%
.
The remaining markets are supplemented by unselected manufacturers Qilu and Hunan Kelun
.

Moxifloxacin Sodium Chloride Injection

In 2020, the sales of Moxifloxacin Sodium Chloride Injection in sample hospitals were 611 million yuan.
Compared with the sales in 2019, the average unit price has decreased, and the sales volume has also decreased slightly
.

Judging from the data in the first half of 2021, it can be predicted that the sales volume of moxifloxacin sodium chloride injection in 2021 will be close to that in 2020, but since the unit price has dropped by more than 60%, sales will also drop by about 60%
.

Judging from the sales share in the first half of 2021, the sales share of the two selected manufacturers has increased significantly
.
Tianjin Hongri’s product sales and sales volume accounted for 18% and 40%; Hainan AGCO’s product sales and sales volume accounted for 28% and 13%
.
The rest of the market is divided by the unselected manufacturers Bayer, Nanjing Zhengda Tianqing, Sichuan Kelun, Sichuan Meidakang Huakang, Shandong Qidu, Chengdu Zhengkang, Yangtze River Pharmaceutical, Jiangsu Zhengda Fenghai and Shijiazhuang Siyao
.

Levetiracetam Concentrated Solution for Injection

In 2020, the sales of levetiracetam injection concentrated solution in the sample hospitals were 24 million yuan.
Compared with 2019, the sales have increased, the average unit price has decreased slightly, and the sales volume has doubled
.

Judging from the data in the first half of 2021, it can be predicted that the sales volume of levetiracetam injection concentrated solution in 2021 will increase by three times compared with 2020, but the unit price will drop by 75%, so sales will be basically the same
.

Judging from the sales share in the first half of 2021, the selected manufacturers Patheon/UCB, Chongqing Shenghuaxi, Hainan Puli, Hebei Renheyikang accounted for 88% and 96% of the product sales and sales volume.
The rest of the market is composed of Two manufacturers, Chengdu Tiantaishan Pharmaceutical and Jichuan Pharmaceutical, were not selected as supplements
.

Azacitidine for Injection

In 2020, the sales of azacitidine for injection in the sample hospitals were 126 million yuan.
Compared with 2019, the sales have increased, the average unit price has decreased slightly, and the sales volume has doubled
.
Judging from the data in the first half of 2021, it can be predicted that the sales volume of azacitidine for injection in 2021 will increase compared to 2020, but the unit price will drop by more than 50%, so sales will decline
.

Judging from the sales share in the first half of 2021, the sales share of the two selected manufacturers has increased significantly
.
Sichuan Huiyu’s product sales and sales volume accounted for 29% and 47%, and CP Tianqing’s product sales and sales volume accounted for 27% and 33%.
The remaining market was occupied by the unselected manufacturer Xinji
.

B has not entered the collection of large varieties

In 2020, the sample hospital sales exceeded 700 million yuan and did not enter the collection of injections: dezocine (2.
060 billion yuan), meropenem (1.
879 billion yuan), cefoperazone and sulbactam sodium (1.
566 billion yuan) , Piperacillin and tazobactam sodium (1.
436 billion yuan), tigecycline (886 million yuan), imipenem and cilastatin (832 million yuan), voriconazole (816 million yuan), caspofungin acetate (800 million yuan) and omeprazole (777 million yuan)
.

Review situation

1.
Dezocine injection: As of October 19, 2021 (the same below), the only manufacturers of this product are Yangzijiang Pharmaceutical and Nanjing Youke Pharmaceutical, and neither of them has submitted the consistency evaluation supplement for dezocine injection.
Apply
.
Enhua Pharmaceuticals and Tianjin Pharmaceutical Research Institute have applied for production under review, while China Resources Double-Crane has not approved for production
.

2.
Meropenem for injection: Shenzhen Haibin Pharmaceutical, Hanhui Pharmaceutical, CSPC Ouyi and Shenzhen Huayao Nanfang Pharmaceutical have passed the consistency evaluation.
The original research company is Sumitomo Pharmaceutical of Japan
.

3.
Cefoperazone Sodium and Sulbactam Sodium for Injection: There are 331 domestic approvals for this variety, and 8 consistency evaluation applications have 16 acceptance numbers, but none of them have passed the consistency evaluation and there is no import production approval
.

4.
Piperacillin sodium and tazobactam sodium for injection: 6 batches of Qilutian, Huishi Pharmaceutical, and North China Pharmaceutical have passed the consistency evaluation for this variety.
The original research is Pfizer and Wyeth
.

5.
Tigecycline for injection: Four companies including Chia Tai Tianqing, Jiangsu Hausen, Zhejiang Hisun and Fuan Pharmaceutical Group Hubei People's Pharmaceutical have passed the consistency evaluation.
The original research is Wyeth
.

6.
Imipenem-Cistatin Sodium for Injection: At present, there are 5 domestic production approvals with 10 approvals, 5 import approvals with 11 approvals, and consistency evaluation applications have 2 and 4 acceptance numbers, but both Failed to pass the consistency evaluation
.

7.
Voriconazole for injection: There are currently 4 domestic approvals with 4 batch numbers, the original research is Pfizer, there are 22 acceptance numbers for generic drug registration applications for category 4, and one application for consistency evaluation is Sichuan Meidakang Huakang Pharmaceutical.
But none of them passed the consistency evaluation
.

8.
Caspofungin acetate for injection: There are 10 domestic approvals, the original research is Merck, 1 Hengrui has passed the consistency evaluation, and 3 generic drugs 4 and 5.
2 registration applications (Qilu, Shenzhen China Resources Jiuxin, Guangzhou Poinsettia) has 5 acceptance numbers, and there are 2 applications for consistency evaluation (Zhengda Tianqing, Hangzhou Sino-US East China) and 3 acceptance numbers
.

9.
Omeprazole Sodium for Injection: There are many domestic manufacturers with a total of 126 approval numbers.
Now there are Jiangsu Osaikang, Tianjin Central Pharmaceutical, Guangzhou Poinsettia, Shandong New Times Pharmaceutical, Shandong Yuxin Pharmaceutical, etc.
Eighteen companies have passed the consistency evaluation one after another, and a number of them are still in the review process without approval for import production
.

Who is most likely to enter the collection?

Judging from the consistency evaluation of the nine injection products with the largest sales in the above market and the manufacturer’s approval, the following will soon enter the centralized procurement: meropenem for injection, piperacillin sodium for injection and tazobactam sodium for injection There are 4 varieties of tigecycline and omeprazole sodium for injection
.
Dezocine injection, cefoperazone sodium and sulbactam sodium for injection, imipenem-cilastatin sodium for injection, voriconazole for injection, and caspofungin acetate for injection, five varieties will pass the consistency evaluation or obtain imitations.
It is possible to enter the centralized procurement only after the approval of the 4 types of pharmaceuticals
.
And once it enters the collection, these hot varieties will start another "fight"
.

This content is the original creation of the "Pharmaceutical Economic News" financial media platform
.
Without the authorization of "Pharmaceutical Economic News", it may not be used in any way, including reprinting, extracting, copying, or creating mirror images
.
If you need authorization, please contact: 020-37886610 or 020-37886753; yyjjb@21cn.
com
.